Analyst Price Target is $13.33
▲ +330.11% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Alpha Tau Medical in the last 3 months. The average price target is $13.33, with a high forecast of $23.00 and a low forecast of $8.00. The average price target represents a 330.11% upside from the last price of $3.10.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in Alpha Tau Medical. This Buy consensus rating has held steady for over two years.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.